NASDAQ$TRAW
Traws Pharma Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Announced financial results for the twelve months ended December 31, 2021, and provided a business update.
Onconova Therapeutics reported its full-year 2021 financial results, with cash and cash equivalents at $55.1 million. The company is progressing with its clinical trials, particularly the Phase 1 program for narazaciclib and investigator-sponsored studies for rigosertib.
- Cash and cash equivalents were $55.1 million as of December 31, 2021, compared to $19.0 million as of December 31, 2020.
- Research and development expenses were $7.3 million for 2021, compared with $16.9 million for 2020.
- General and administrative expenses were $9.4 million for 2021, compared with $8.3 million for 2020.
- Net loss for 2021 was $16.2 million, or $0.96 per share.
Headline financials
Revenue & EPS history
Onconova · Revenue · Quarterly
$56K
Forward guidance
Onconova anticipates sufficient cash to fund clinical trials and business operations for at least two years and is focused on advancing its clinical programs, particularly narazaciclib and rigosertib.
Tailwinds
- On track to identify a recommended Phase 2 dose for narazaciclib in the second half of the year.
- Narazaciclib shows low nanomolar activity against kinases associated with tumor growth, metastasis, and potentially drug resistance.
- Reported compelling preliminary clinical data from an investigator-sponsored study of rigosertib in RDEB-associated SCC.
- On track to report updated data from the Phase 1/2a study evaluating rigosertib-nivolumab combination therapy in KRAS+ NSCLC this year.
- To open a Phase 2 metastatic melanoma trial of oral rigosertib plus pembrolizumab in the first half.
Headwinds
- Forward-looking statements involve risks and uncertainties.
- Success and timing of clinical trials are subject to uncertainties.
- Regulatory agency and institutional review board approvals of protocols are uncertain.
- Collaborations may face uncertainties.
- Market conditions can impact results.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2021
-0.7%
Avg return
Earnings day
-2.6%
Avg return
5 days after
-5.0%
Avg return
30 days after
25%
9 / 36 earnings
Positive
+22.6%
Q3 2025
Best reaction
-22.6%
Q4 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +15.3% | — | — | |
| Q4 2026 | -22.6% | -12.6% | +18.2% | |
| Q3 2025 | +22.6% | +19.2% | +31.6% | |
| Q2 2025 | -1.2% | -18.3% | +16.5% | |
| Q1 2025 | -3.6% | +1.4% | +2.1% | |
| Q4 2024 | +6.0% | -1.0% | -30.5% | |
| Q3 2024 | -11.7% | -16.8% | -17.7% | |
| Q2 2024 | -2.7% | +5.4% | -5.4% | |
| Q1 2024 | -2.5% | -1.5% | -9.1% | |
| Q4 2023 | -1.5% | -19.8% | -34.7% | |
| Q3 2023 | -3.1% | +0.0% | +15.4% | |
| Q2 2023 | -2.0% | -11.2% | -20.4% | |
| Q1 2023 | -4.0% | -5.3% | +53.3% | |
| Q4 2022 | -3.9% | -5.3% | +51.3% | |
| Q3 2022 | +18.3% | +36.6% | +7.0% | |
| Q2 2022 | +3.9% | -1.6% | -10.1% | |
| Q1 2022 | -1.6% | -2.1% | -26.1% | |
| Q4 2021 | +10.0% | +13.7% | +0.6% | |
| Q3 2021 | +1.2% | -1.5% | -18.3% | |
| Q2 2021 | -4.4% | -11.8% | -1.2% | |
| Q1 2021 | -3.1% | -9.0% | -26.4% | |
| Q4 2020 | +0.0% | -3.6% | -97.0% | |
| Q3 2020 | +0.0% | +3.8% | +42.3% | |
| Q2 2020 | -3.6% | -6.4% | -79.1% | |
| Q1 2020 | +0.0% | +5.6% | +69.4% | |
| Q3 2019 | -7.1% | -16.7% | -35.7% | |
| Q2 2019 | -2.1% | -5.6% | +7.3% | |
| Q1 2019 | -6.3% | -11.5% | -15.9% | |
| Q3 2018 | -11.5% | -3.1% | -25.1% | |
| Q2 2018 | -9.1% | -6.8% | +11.4% | |
| Q1 2018 | -5.4% | -2.7% | +40.5% | |
| Q3 2017 | -2.1% | -16.8% | -22.1% | |
| Q2 2017 | -0.5% | -16.7% | -19.3% | |
| Q1 2017 | -0.5% | -0.5% | -9.0% | |
| Q3 2016 | +11.0% | +28.7% | -15.8% | |
| Q2 2016 | +2.5% | +4.2% | -21.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro